Aditum Bio has announced the formation of Vitalli Bio, a portfolio company created for the development of new therapies for immunological disorders.
Aditum Bio is a biotech investment company founded in 2019 by former Novartis CEO Joe Jimenez and former president of Novartis Institutes for BioMedical Research (NIBR) Mark Fishman.
Vitalli Bio was formed in connection with the license of a dual selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) and Bruton’s tyrosine kinase (BTK) from Daewoong Pharmaceutical, which is expected to close in early May. The compound will be renamed VIT-801, and is expected to enter a phase 1 study in 2023.
Options on early stage inhibitors
Unlike current treatments, which are generally limited to inhibiting only individual cell types, VIT-801 is a dual-target inhibitor that simultaneously inhibits B cells, T cells and other immune cells, potentially providing a best-class profile in immune disorders where multiple cell types involved. In addition to VIT-801, Vitalli Bio will be given the option to license an early-stage dual target inhibitor being developed by Daewoong.
“Additum Bio’s translational drug approach is unique in the industry, and we are excited to move this exciting compound into the clinic in immunological disorders,” said Jimenez, co-founder and managing director of Aditum Bio.
Fishman, co-founder and chair of the medical and scientific advisory board, added: “VIT-801 has a unique profile of selectively inhibiting a variety of relevant immune cells, demonstrating that it has the potential to represent a safe and effective alternative in these difficult situations. -to-treat population.”
Vitalli Bio is the ninth company launched by Aditum Bio, whose mission is to give a large patient population access to medicines that might otherwise go undeveloped. To accelerate the drug market, Aditum Bio developed an incubator model, focusing on the translational phase of drug development.
The company says the “spin out” model enables an agile start-up culture with a team of dedicated managers supported by Aditum’s internal team of operational and technical experts, ranging from nonclinical pharmacology and CMC, to regulatory affairs and clinical operations. .
About Bio Access
Aditum Bio focuses on underlying mechanisms of disease, licenses promising drug candidates geared towards such pathophysiologies, and establishes individual companies dedicated to getting each candidate through Phase II clinical trials. Aditum Bio uses data, software and technology to help bring innovative drugs through the clinical trial phase faster and at a lower cost than traditional pharmaceutical companies.